Scalper1 News
Biotech stock Kite Pharma (KITE) continued to slide Friday after dropping 9% Thursday, and Cowen & Co. analyst Eric Schmidt thinks he knows why. “Recall that Kite is enrolling six patients in the Phase I portion of KTE-C19’s Phase I/II trial in refractory diffuse large B-cell lymphoma (DLBCL),” Schmidt wrote in a research note late Thursday. “Kite shares traded down today and based on our conversations with investors throughout the day, we believe Scalper1 News
Scalper1 News